HANGZHOU, China and SHANGHAI and BOSTON, Dec. 2, 2025 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as “Lynk Pharmaceuticals”), a clinical-stage innovative drug development company focused on developing innovative therapies for immune and inflammatory diseases, today announced that its innovative TYK2 allosteric inhibitor, LNK01006, has been approved by U.S. Food and Drug Administration (FDA) for human clinical trials.

LNK01006 is a highly brain-penetrant, potent, and selective oral TYK2 allosteric inhibitor targeting the JH2 domain. TYK2 is a key regulator of the IL-12 and IL-23 signaling pathways, which promote Th1 and Th17 cell differentiation. Th1/Th17 cells play a central role in central nervous system (CNS) inflammatory diseases such as multiple sclerosis (MS). Inhibiting TYK2 reduces the activation of pro-inflammatory T cells, thus lowering CNS inflammation. LNK01006 demonstrated high brain penetration in preclinical species and promising efficacy in treating and preventing multiple sclerosis in MS disease models, presenting a great potential for treating neuroinflammatory diseases. 

Dr. Michael Lawrence Vazquez, Co-founder and Executive Vice President of Lynk Pharmaceuticals, said, “Obtaining FDA IND approval for LNK01006 marks a key milestone in our pursuit of innovative TYK2 allosteric mechanisms. Our CNS penetrant TYK2 inhibitor was specifically designed to cross the BBB (blood brain barrier) and afford high CNS exposure. We leveraged medicinal chemistry principles and molecular design to optimize the physical properties, potency and selectivity. Allosteric TYK2 inhibitors (binding the pseudokinase domain) can achieve high specificity, avoiding cross‑inhibition of JAK1/2/3, thus a selective TYK2 inhibitor could dampen pathogenic immune signaling without broadly suppressing other JAK pathways. We look forward to advancing this promising molecule into human clinical trials and bringing new therapeutic options to treat patients suffering from neurodegenerative diseases.”

Dr. Jun Wang, Co-founder and Chief Scientific Officer of Lynk Pharmaceuticals, said, “LNK01006 is a novel brain-penetrant allosteric TYK2 inhibitor designed to modulate CNS-relevant inflammatory pathways, including type I interferons and IL-12/IL-23 signaling. Supported by strong evidence from human genetics and patient gene-expression studies and by robust efficacy in preclinical neuroinflammation models, LNK01006 represents a promising new therapeutic approach for CNS diseases with significant unmet need. We look forward to advancing its clinical validation.”

About Lynk Pharmaceuticals

Lynk Pharmaceuticals, a clinical stage company, was founded by senior drug R&D experts and executives from Pfizer, Merck, and Johnson & Johnson. Lynk Pharmaceuticals is dedicated to the discovery and development of innovative drugs for the treatment of immune and inflammatory diseases. Driven by a higher goal, Lynk Pharmaceuticals aims to be a market leader to address unmet medical demands by the development of innovative therapies. We thrive to provide differentiated innovative therapies to benefit patients globally. To date, Lynk Pharmaceuticals has independently developed several innovative new drug candidates and successfully completed a number of clinical studies.

SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ — AI deep learning company AIPro unveiled its AI-based early wildfire and fire detection solutions at Korea’s leading national safety and security exhibitions this fall.

The events served as a platform for AI PRO to demonstrate the latest features and real-world applications of its flagship technology, AI-BOX, highlighting new possibilities for AI adoption in both public and industrial safety sectors.

AIPro participated in the 2025 Korea International Safety & Security Expo (September 17–19, KINTEX) and the 2025 International Security Industry Exhibition (October 22–25, Songdo Convensia).

During the exhibitions, the company presented its successful case studies, including a pilot project at Korea Hydro & Nuclear Power (KHNP), a wildfire and EV fire detection system for the KAMCO Training Institute, and its selection as an innovative procurement product by the Public Procurement Service (PPS) — showcasing the proven effectiveness and scalability of its AI video analytics technology.

The company’s AI-BOX series enables high-precision video analytics using existing CCTV infrastructure, eliminating the need for costly equipment replacement.

With customized on-site AI models and low-power system design, AI PRO’s technology delivers energy efficiency and aligns with the government’s eco-friendly and smart safety initiatives, attracting strong interest from the public sector.

A spokesperson for AIPro stated, “This exhibition was not just a demonstration of our technology, but an opportunity for visitors to see our AI safety solutions operating in real-world environments. We plan to strengthen partnerships with domestic and international buyers and public institutions to accelerate market expansion.”

Building on its exhibition success, AIPro plans to expand the application of its AI detection systems to forestry agencies, local governments, and public facilities, while collaborating with drone, robotics, and IoT companies to evolve into an integrated intelligent disaster and safety platform provider.

SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ — SURFIRAN CO LTD has unveiled new premium products made with saffron—known globally as the world’s most expensive spice—further solidifying the company’s leadership in Korea’s emerging gourmet market.

The new lineup focuses on maximizing saffron’s golden color, deep aroma, and health properties while making the ingredient more accessible for everyday cooking. SURFIRAN CO LTD oversees sourcing, R&D, manufacturing, and distribution to maintain consistent premium quality.

“Although saffron remains unfamiliar to many Koreans, interest is rapidly growing with the rise of gourmet and wellness trends,” the company stated. “We are committed to offering saffron products that seamlessly fit into Korean dining habits.”

The company plans to expand its saffron portfolio into beverages, fermented foods, condiments, and other culinary categories.

Licence variation will enable Singapore merchants to accept payments from the rest of the world; global merchants to offer popular local Singapore payment methods.

SINGAPORE, Dec. 2, 2025 /PRNewswire/ — Thunes today announced that it has received In-Principle Approval (IPA) for a variation of its Major Payment Institution licence (MPI) from the Monetary Authority of Singapore.

This In-Principal Approval marks a significant milestone in Thunes’ growth journey and demonstrates the company’s commitment to being one of the most trusted and innovative fintechs operating from Singapore. 

Subject to the grant of the MPI licence variation, Thunes will be positioned to expand its global offering in Singapore. This future state will empower merchants to access a wider range of payment solutions and accept payments from customers from the rest of the world using popular international and local payment methods. Specifically, this will allow Singapore merchants to accept payments via popular international methods, while also enabling global merchants in key markets across the Middle East, South Asia, Africa, and Europe to accept leading Singapore payment methods such as PayNow and GrabPay.

Today, Thunes’ Network gives its Members access to more than 320 local payment methods worldwide, enabled by our group’s portfolio of over 50 financial service licenses across the globe.

Upon the grant of the MPI licence variation, Thunes Asia will be authorised, in addition to its existing cross-border money transfer service, to provide account issuance, domestic money transfer, merchant acquisition, and e-money issuance services.

Peter De Caluwe, Co-founder and CEO of Thunes Group, said: “This In-Principle Approval from MAS is a major step forward for Thunes’ global strategy and a catalyst for growth. As our global headquarters, Singapore is the center of our governance and innovation, and with this approval, we’re doubling down on our commitment to connect markets, empower merchants, and expand our trusted Direct Global Network across the world.”

Ruwan De Soyza, General Counsel at Thunes Group, added: “Strong governance and a commitment to regulatory excellence have always been at the heart of how Thunes operates. This milestone reflects our unwavering commitment to doing business the right way. Our Thunes’ robust Fortress Compliance Platform underpins everything we do, ensuring our Members can trust every transaction that flows through our Network.”

This In-Principle Approval is a key milestone in Thunes’ leadership in building a safer, more connected global payments ecosystem that empowers businesses and consumers to transact seamlessly across borders. The company continues to work towards meeting all remaining requirements for the approval.

FOOTNOTES

An In-Principle Approval (IPA) in respect of a licence variation application reflects MAS’ view that the applicant’s licence variation application may be approved upon the fulfilment of specified conditions and provided there are no material adverse developments affecting the applicant. An IPA does not constitute an approval for the Company to provide an account issuance service; a domestic money transfer service; a merchant acquisition service; and an e-money issuance service at this juncture. MAS reserves the right to rescind the IPA in circumstances where it considers appropriate.

ENDS

Contact:

WE Communications, thunes@wecommunications.com

Anna Birdsall-Strong, Director of Brand and Public Relations, anna.birdsall@thunes.com

• Three Singapore-headquartered companies were recognized for workplace culture in the inaugural 2025 Fortune 100 Best Companies to Work For™ Southeast Asia list.
• Over 1.3 million employees from ten countries were invited to share their views.
• Placing third overall, Capella Hotels & Resorts are helping grow Singapore’s reputation for excellence in both hospitality and employee wellbeing.

SINGAPORE, Dec. 2, 2025 /PRNewswire/ — Singaporean employers have featured prominently on the prestigious, inaugural Fortune 100 Best Companies to Work For™ Southeast Asia list, published today Fortune in collaboration with Great Place To Work® ASEAN & ANZ.

The Fortune 100 Best Companies to Work For list – first published in the US in 1998 – has long been one of the most recognised workplace benchmarks in North America. This year marks a major expansion of that legacy into Southeast Asia. More than 1.3 million employees across ten markets were invited to assess trust, fairness and support at work, with over 550,000 verified survey responses shaping the inaugural regional rankings.

Evelyn Kwek, Managing Director of Great Place To Work ASEAN & ANZ, said the list reflects a region-wide commitment to strengthening workplace culture.

“For decades, the Fortune 100 Best Companies to Work For List defined the gold standard for great workplaces in the US. Following the list’s global expansion – with the launch of the inaugural Europe list in 2024 – Southeast Asia now joins this international standard of excellence. This first-ever list reflects a diverse and dynamic region that is coming into its own by recognizing organizations that have intentionally built environments where people feel trusted and supported to do their best work. The decades of research and millions of employee voices collected in our data has shown that when that trust is strong, businesses grow in ways that lift up people, communities, and entire economies.”

The Fortune 100 Best Companies to Work For Southeast Asia list is the region’s most comprehensive measure of the employee experience, based on Great Place To Work’s proprietary Trust Index™ Survey. Rankings are driven primarily by confidential employee feedback, with company-provided information used to confirm basic eligibility and context. Only companies with consistently high survey responses from employees, regardless of their role, department, or status in the company, can secure a placement on the list.

Singapore’s Leading Workplaces Recognized
The Fortune 100 Best Companies to Work For® Southeast Asia list is compiled using rigorous benchmarks that assess employee trust and workplace culture. Companies headquartered in Singapore, or with a significant local footprint, that ranked within the 100 include:

#3 Capella Hotels & Resorts (Singapore headquarters) 
“Being recognised in the inaugural Fortune 100 Best Companies to Work For in Southeast Asia is a meaningful recognition for all of us at Capella Hotels and Resorts. It amplifies our belief that exceptional hospitality begins with a workplace where our colleagues feel valued, supported, and inspired,” said Richmond Kok, Senior Director, Human Resources (Learning & Talent Development)
#18 Micron Technology
#21 Visa
#33 HP
#31 SC Johnson 
#39 Jebsen & Jessen Group (Singapore headquarters) 
#86 ST Telemedia Global Data Centres (Singapore headquarters) 

The full Fortune 100 Best Companies to Work For™ Southeast Asia list is available here: https://greatplacetowork.com.sg/best-companies-to-work-for-southeast-asia-2025/

SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ — Leaders Dental Laboratory (branded globally as LEADERS DENTAL), a leading digital dental laboratory in Korea, is rapidly strengthening its presence in the global digital dentistry market with its flagship product, the surgical guide. Backed by recent export achievements in five countries—including the United Kingdom, Japan, and Taiwan—the company is expanding exports of its integrated digital solution packages to align with the global shift from single implant components to fully systemized workflows.

LEADERS DENTAL operates a large-scale digital manufacturing facility spanning over 300 pyeong, equipped with industrial-grade 3D printers, milling machines, and advanced digital production lines. The company has established a fully digital workflow using CT imaging and intraoral scanners for both implant prosthetics and surgical guide production, enabling exceptionally high precision.

Its surgical guides reduce reliance on the clinician’s manual expertise, supporting safer and more accurate implant procedures. This innovation has earned strong praise from partners in markets such as Hong Kong and Taiwan, who regard the product as a next-generation K-digital dental solution.

Aiming to become “the central hub of the digital dentistry ecosystem,” LEADERS DENTAL plans to accelerate production automation through AI-CAD design systems and advanced 3D printing technologies. A company representative stated, “Expanding our digital dental solutions overseas is more than exporting products—it is a way to introduce Korea’s advanced medical technology to the world.” The representative added that the company will strengthen its domestic market leadership while expanding sales in China, broader Asia, and the Middle East over the next one to two years.

LYON, France, Dec. 2, 2025 /PRNewswire/ — NEJM Evidence, a journal of the New England Journal of Medicine Group, has published an article titled “Validation of a Saliva microRNA Signature for Endometriosis,” dedicated to the saliva-based diagnostic test developed by Ziwig.

The publication reports the results of a prospective, independent, multicenter clinical study conducted in France. The study enrolled 971 symptomatic women aged 18 to 43 years across 17 public and private hospitals.

High-performance saliva-based diagnosis

The Ziwig Endotest® was evaluated through the analysis of 109 salivary microRNAs, combining next-generation sequencing (NGS) with artificial intelligence. Diagnostic interpretations were performed blindly, without prior knowledge of the patients’ clinical status, ensuring full methodological independence and robustness.

The NEJM Evidence publication highlights exceptional diagnostic performance:

• Sensitivity: 97.3%
• Specificity: 94.1%
• Overall accuracy: 96.6%
• Positive predictive value: 98.2%
• Negative predictive value: 91.3%

These results show that more than 96 out of 100 women receive an accurate diagnostic result with Ziwig Endotest®. Performance remained consistent across all subgroups, regardless of hormonal treatment, analgesic use, inclusion site, or sequencing conditions, confirming the reliability and reproducibility of the test in real-world settings.

Now available for routine prescription in clinical practice

Within the framework of the French national early access program for breakthrough technologies (Forfait Innovation), Ziwig Endotest® is now reimbursed and available on medical prescription in 100 hospitals across France.

It is indicated for women aged 18 to 43 years with chronic pelvic pain suggestive of endometriosis, when imaging results are normal or inconclusive. The test can be prescribed outside any research study, providing women with rapid, non-invasive, and accurate access to diagnosis.

A major advance for women’s health

Endometriosis affects around 10% of women of reproductive age, with diagnostic delays often exceeding seven years. The validation and clinical deployment of Ziwig Endotest® mark a major step forward toward earlier, simpler, and more equitable diagnosis.

“This publication in NEJM Evidence is a major step forward for science and for women affected by endometriosis. We are deeply grateful to all the women, hospitals, and healthcare professionals whose commitment and support have been essential in bringing this innovation to patients,” said Yahya El Mir, Founder and President of Ziwig.

For more information: www.ziwig.com

Contact presse – Finn Partners
Marie-Hélène Coste & Aurélia Adloff
06 20 89 49 03 / 06 89 38 94 70
sante@finnpartners.com